EFFECT OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY LINE OF THERAPY: INTERIM RESULTS FROM THE PHASE 3 ASPIRE STUDY
Author(s): ,
Meletios A. Dimopoulos
Affiliations:
National and Kapodistrian University of Athens,Athens,Greece
,
A. Keith Stewart
Affiliations:
Mayo Clinic,Scottsdale,United States
,
S. Vincent Rajkumar
Affiliations:
Mayo Clinic,Rochester,United States
,
Tamás Masszi
Affiliations:
St István and St Laszlo Hospital,Budapest,Hungary
,
Ivan Špi?ka
Affiliations:
General University Hospital in Prague,Prague,Czech Republic
,
Albert Oriol
Affiliations:
Institut Català d’Oncologia, Hospital Germans Trias i Pujol,Barcelona,Spain
,
Roman Hájek
Affiliations:
University Hospital Brno and Faculty of Medicine, University of Ostrava,Ostrava,Czech Republic
,
Laura Rosiñol
Affiliations:
Hospital Clínic de Barcelona,Barcelona,Spain
,
David Siegel
Affiliations:
John Theurer Cancer Center at Hackensack University,Hackensack,United States
,
Georgi G. Mihaylov
Affiliations:
Queen Joanna University Hospital,Sofia,Bulgaria
,
Vesselina Goranova-Marinova
Affiliations:
Hematology Clinic University Multiprofile Hospital for Active Treatment,Plovdiv,Bulgaria
,
Péter Rajnics
Affiliations:
Mór Kaposi Teaching Hospital,Kaposvár,Hungary
,
Aleksandr Suvorov
Affiliations:
First Republican Clinical Hospital of Udmurtia,Izhevsk,Russian Federation
,
Ruben Niesvizky
Affiliations:
Weill Cornell Medical College,New York,United States
,
Andrzej Jakubowiak
Affiliations:
University of Chicago Medical Center,Chicago,United States
,
Jesus San-Miguel
Affiliations:
Clinica Universidad de Navarra,Navarra,Spain
,
Heinz Ludwig
Affiliations:
Wilhelminen Cancer Research Institute, Wilhelminenspital,Vienna,Austria
,
Naseem Zojwalla
Affiliations:
Onyx Pharmaceuticals, Inc., an Amgen subsidiary,South San Francisco,United States
,
Margaret Tonda
Affiliations:
Onyx Pharmaceuticals, Inc., an Amgen subsidiary,South San Francisco,United States
,
Xinqun Yang
Affiliations:
Onyx Pharmaceuticals, Inc., an Amgen subsidiary,South San Francisco,United States
,
Philippe Moreau
Affiliations:
University of Nantes,Nantes,France
Antonio Palumbo
Affiliations:
University of Torino,Torino,Italy
EHA Learning Center. Dimopoulos M. Jun 13, 2015; 103134
Disclosure(s): National and Kapodistrian University of Athens
Prof. Dr. Meletios A Dimopoulos
Prof. Dr. Meletios A Dimopoulos

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: S427

Type: Oral Presentation

Presentation during EHA20: From 13.06.2015 11:45 to 13.06.2015 12:00

Location: Room A2+3

Background
Previously reported results from ASPIRE (NCT01080391; N=792 patients) showed that carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma, with a favorable benefit-risk profile (Stewart et al. N Engl J Med 2015;372:142–52).

Aims
A secondary analysis of efficacy and safety results from patients treated with KRd or Rd after first relapse (1 prior line of therapy) vs ≥2 prior lines of therapy in the ASPIRE study is presented.

Methods
Adults with relapsed multiple myeloma who received 1–3 prior lines were eligible. Patients were randomized (1:1) to KRd or Rd. All patients received lenalidomide (25 mg) on days 1–21 and dexamethasone (40 mg) on days 1, 8, 15, and 22 of a 28?day cycle. Patients in the KRd arm received carfilzomib as a 10?min infusion on days 1, 2, 8, 9, 15, and 16 during cycles 1–12 (20 mg/m2 [days 1 and 2 of cycle 1]; 27 mg/m2 thereafter). Carfilzomib was omitted on days 8 and 9 during cycles 13–18 and was not administered beyond 18 cycles. All patients provided informed consent.

Results
Median PFS for patients receiving 1 prior line (n=341) was 29.6 months (95% confidence interval [CI]: 23.2–33.5) for KRd vs 17.6 months (95% CI: 15.0–22.2) for Rd (hazard ratio [HR]: 0.694; P=.0083). Median PFS for patients receiving ≥2 prior lines (n=451) was 25.8 months (95% CI: 22.2–31.0) for KRd vs 16.7 months (95% CI: 13.9–22.0) for Rd (HR: 0.688; P=.0017). Best overall responses in patients who received 1 vs ≥2 prior lines of therapy are presented in the Table. Overall response rates (partial response or better) were 87.0% (KRd) vs 70.1% (Rd) in patients with 1 prior line and 87.3% (KRd) vs 64.4% (Rd) in patients with ≥2 prior lines. In patients with 1 prior line, 33.7% (KRd) vs 7.0% (Rd) achieved a complete response (CR) or better, including 12.5% (KRd) and 3.2% (Rd) who achieved a stringent complete response (sCR). In patients with ≥2 prior lines, 30.2% (KRd) vs 10.9% (Rd) achieved a CR or better, including 15.6% (KRd) and 5.0% (Rd) who achieved a sCR. Adverse events (AEs) grade ≥3 were reported in 85.7% (KRd) and 79.9% (Rd) of patients who received 1 prior line of therapy and 81.9% (KRd) and 81.3% (Rd) of patients who received ≥2 prior lines. AEs of interest (grade ≥3; grouped terms) included dyspnea (1 prior line: 2.7% [KRd] and 2.6% [Rd]; ≥2 prior lines: 3.3% [KRd] and 1.7% [Rd]); cardiac failure (1 prior line: 3.3% [KRd] and 1.9% [Rd]; ≥2 prior lines: 4.3% [KRd] and 1.7% [Rd]); ischemic heart disease (1 prior line: 4.9% [KRd] and 1.3% [Rd]; ≥2 prior lines: 1.9% [KRd] and 2.6% [Rd]); hypertension (preferred term; 1 prior line: 3.8% [KRd] and 0.6% [Rd]; ≥2 prior lines: 4.8% [KRd] and 2.6% [Rd]); and acute renal failure (1 prior line: 3.3% [KRd] and 3.2% [Rd]; ≥2 prior lines: 3.3% [KRd] and 3.0% [Rd]).

Summary
The use of KRd led to a 1-year improvement in median PFS vs Rd after first relapse, and a 9-month improvement in median PFS vs Rd in patients with ≥2 prior lines of therapy, with similar HRs. KRd had a favorable benefit–risk profile compared with Rd after 1 and ≥2 prior lines of therapy in patients with relapsed multiple myeloma.

Keyword(s): Immunomodulatory thalidomide analog, Myeloma, Phase III, Proteasome inhibitor



Session topic: Multiple myeloma: Clinical studies 2
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings